LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

Arcus Biosciences Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

9.24 -1.18

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

8.93

Max

9.31

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-18M

-112M

Pardavimai

2M

28M

Pelnas, tenkantis vienai akcijai

-1.14

Pelno marža

-400

Darbuotojai

627

EBITDA

-34M

-122M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+170.48% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

90M

1.1B

Ankstesnė atidarymo kaina

10.42

Ankstesnė uždarymo kaina

9.24

Naujienos nuotaikos

By Acuity

50%

50%

177 / 380 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Arcus Biosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-13 22:33; UTC

Įsigijimai, susijungimai, perėmimai

Millicom to Acquire Telefonica Ecuador for $380 Million

2025-06-13 23:50; UTC

Įsigijimai, susijungimai, perėmimai

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

2025-06-13 23:20; UTC

Įsigijimai, susijungimai, perėmimai

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

2025-06-13 23:09; UTC

Įsigijimai, susijungimai, perėmimai

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

2025-06-13 23:03; UTC

Įsigijimai, susijungimai, perėmimai

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

2025-06-13 22:18; UTC

Įsigijimai, susijungimai, perėmimai

Millicom to Acquire Telefonica Ecuador for $380M

2025-06-13 22:04; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Better Data Facilitate Investments In Oil Patch -- Market Talk

2025-06-13 21:42; UTC

Įsigijimai, susijungimai, perėmimai

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

2025-06-13 21:35; UTC

Įsigijimai, susijungimai, perėmimai

Bunge: Outside Date Extended to July 3

2025-06-13 21:35; UTC

Įsigijimai, susijungimai, perėmimai

Bunge: Subject to Satisfaction of Remaining Conditions, Bunge and Sellers Expect to Complete Transaction July 2

2025-06-13 21:34; UTC

Įsigijimai, susijungimai, perėmimai

Bunge Gets Mexico Approval for Viterra Deal

2025-06-13 21:32; UTC

Įsigijimai, susijungimai, perėmimai

Bunge Gets China Approval for Viterra Deal

2025-06-13 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-06-13 20:45; UTC

Įsigijimai, susijungimai, perėmimai

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

2025-06-13 20:34; UTC

Įsigijimai, susijungimai, perėmimai

Anne Wojcicki Wins Bidding for 23andMe -- Update

2025-06-13 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

2025-06-13 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

2025-06-13 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

2025-06-13 19:30; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2025-06-13 19:12; UTC

Rinkos pokalbiai

Oil Futures Jump As Israel Strikes Iranian Targets -- Market Talk

2025-06-13 19:04; UTC

Rinkos pokalbiai

Canada Military Spending Hike to Lift Long-Term Yields -- Market Talk

2025-06-13 18:54; UTC

Rinkos pokalbiai

Correction to Gold Settles Market Talk

2025-06-13 18:01; UTC

Rinkos pokalbiai

Gold Settles at Record High -- Market Talk

2025-06-13 17:40; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls By 3 to 439 -- Market Talk

2025-06-13 17:21; UTC

Rinkos pokalbiai

Dollar Index, Commodities Rise -- Market Talk

2025-06-13 17:02; UTC

Įsigijimai, susijungimai, perėmimai

Advent Proposal Values Spectris at GBP37.63 Per Share, Company Said Monday -- WSJ

2025-06-13 17:02; UTC

Įsigijimai, susijungimai, perėmimai

KKR Is Preparing a Bid for High-Tech Instrument Maker Spectris, Sources Say -- WSJ

2025-06-13 17:02; UTC

Įsigijimai, susijungimai, perėmimai

Private-Equity Firm Is Vying With Advent for the U.K. Company, Sources Say -- WSJ

2025-06-13 17:02; UTC

Įsigijimai, susijungimai, perėmimai

KKR Making Competing Bid for Equipment Maker Spectris -- WSJ

2025-06-13 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Arcus Biosciences Inc Prognozė

Kainos tikslas

By TipRanks

170.48% į viršų

12 mėnesių prognozė

Vidutinis 25.29 USD  170.48%

Aukščiausias 46 USD

Žemiausias 12 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Arcus Biosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

8

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

8.01 / 8.75Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Neutral Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

177 / 380 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.